Launch
Website- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
Specialises in
- Haemato-oncology
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Dr Rakesh Popat is a Consultant Haematologist and Associate Professor with specialist expertise in Multiple Myeloma. He is skilled in managing all aspects of multiple myeloma and has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. His NHS base is at University College Hospital, London where he leads the Myeloma Clinical Trials Program and the Cancer trials portfolio at the NIHR UCLH Clinical Research Facility.
Dr Popat is active both nationally and internationally in developing new treatments for myeloma. He is the Chair of the UK Myeloma Research Alliance and on the leadership boards of the UK Myeloma Forum, the European Myeloma Network and is a member of the International Myeloma Working Group (IMWG).
As part of his training he completed a PhD in novel treatments for Myeloma and was awarded a Fellowship to attend the Dana Farber Cancer Institute, Boston USA to gain further experience.
Areas of interest
Multiple myeloma all aspects, with a specific interest in new treatments
Medical secretaries
- Maureen Bucak
- HCA Healthcare UK at University College Hospital UCH Macmillan Cancer Centre 5th Floor, 235 Huntley Street London NW1 2BU
- 002034471717
- 020 3447 1739
- uclh.popat.privatehcapa@nhs.net
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
-
X0001
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 0-7 days - (1-5)
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (1-5)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (1-5)
-
X3590
Intravenous infusion (as sole procedure) - (1-5)
- Show All (7 )...